Logo

Taiho Exercised its Option to License Arcus’s Domvanalimab and AB308 for NSCLC in Japan and Other Countries

Share this

Taiho Exercised its Option to License Arcus’s Domvanalimab and AB308 for NSCLC in Japan and Other Countries

Shots:

  • Arcus will receive an option exercise fees along with an additional milestone upon achievement of clinical, regulatory, and commercialization milestones along with royalties on net sales of the products under an option and license agreement b/w Taiho and Arcus as reported in Sept 2017
  • Taiho will be responsible for the development and commercialization of domvanalimab and will continue to deliver innovative drugs to patients and others
  • Arcus is conducting the P-II (ARC-7) & P-III (ARC-10) trials of domvanalimab + zimberelimab as 1L treatment of metastatic PD-L1≥50% NSCLC while P-III (PACIFIC-8) trial of domvanalimab + durvalumab  is being initiated in Stage III NSCLC

Ref: Businesswire | Image: Taiho 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions